Prioritizing patient choice in clinical research means meeting people where they are and breaking down the barriers that prevent underrepresented groups from participating in clinical trials. Samantha Eells, Co-Founder and Kristin Croucher, Vice President Clinical Operations & Delivery are presenting the advantages of “The Third Place: Improving Access, Choice and Equity” at SCOPE Europe on Thursday, April 21, 2022. Their presentation is part of the day’s program on “Hybrid Trials, Diversity & Inclusion, Transparency & Patients Partners to Achieve Truly Patient-Centric Design”. CEO David MacMurchy is chairing the event.
“We all agree that access to clinical trials should be fair for every participant,” says Sam. “The reality is that a large proportion of people in need still don’t have access to clinical studies as a treatment option.”
“To provide choices to patients that deliver better clinical trials, you need to have a comprehensive understanding of participants’ potential preferences, to start with,” says Kristin. “Lightship’s virtual-first and hybrid approach to clinical research means that patients can be seen at home, in clinic, or a third place, such as at work or a mobile unit.”
“Some patients may not be comfortable having someone visit them at home,” says David. “Giving people the choice to be seen in a third place strengthens relationships between participants and clinical research staff, which builds trust.”
Approaching patient recruitment in a holistic way enables providers to increase access to clinical trials and boost retention rates, helping deliver studies that are more diverse and more effective.